WO2002038168A3 - Verwendung von selektin-bindenden wirkstoffen zur behandlung von entzündlichen- und tumor-erkrankungen - Google Patents

Verwendung von selektin-bindenden wirkstoffen zur behandlung von entzündlichen- und tumor-erkrankungen Download PDF

Info

Publication number
WO2002038168A3
WO2002038168A3 PCT/EP2001/012874 EP0112874W WO0238168A3 WO 2002038168 A3 WO2002038168 A3 WO 2002038168A3 EP 0112874 W EP0112874 W EP 0112874W WO 0238168 A3 WO0238168 A3 WO 0238168A3
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredients
diseases
inflammatory
selectin
treatment
Prior art date
Application number
PCT/EP2001/012874
Other languages
English (en)
French (fr)
Other versions
WO2002038168A2 (de
Inventor
Renate Stahn
Steffen Goletz
Udo Jeschke
Iduna Fichtner
Reinhard Zeisig
Original Assignee
Nemod Immuntherapie Ag
Renate Stahn
Steffen Goletz
Udo Jeschke
Iduna Fichtner
Reinhard Zeisig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nemod Immuntherapie Ag, Renate Stahn, Steffen Goletz, Udo Jeschke, Iduna Fichtner, Reinhard Zeisig filed Critical Nemod Immuntherapie Ag
Priority to EP01989442A priority Critical patent/EP1448224A2/de
Priority to CA002428141A priority patent/CA2428141A1/en
Priority to US10/416,061 priority patent/US20040191303A1/en
Priority to AU2002227907A priority patent/AU2002227907A1/en
Priority to JP2002540750A priority patent/JP2004534722A/ja
Publication of WO2002038168A2 publication Critical patent/WO2002038168A2/de
Publication of WO2002038168A3 publication Critical patent/WO2002038168A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Selektin-bindenden Wirkstoffen, in Form von Schwangerschaftsproteinen oder deren Fragmenten, von Liposomen, die Calcium-bindende Verbindungen enthalten, aus nativen Quellen stammenden Muzin-Fragmenten oder davon abgeleitet sind oder Mimikry-Verbindungen, die sialylierte Kohlenhydratstrukturen vom Lewis-Typ imitieren, oder deren Kombinationen, zur Behandlung und Prophylaxe von Erkrank-ungen, in deren Verlauf entzündliche Prozesse eine Rolle spielen, wie beispielsweise Autoimmunerkrankungen, Trans-plantationen und Arteriosklerose. Entzündungserkrankungen im Sinne der Erfindung können infektiöser oder nichtinfek-tiöser Natur sein.Gegenstand der Erfindung ist auch die Verwendung dieser Wirkstoffe zur teilweisen oder vollständigen Verhinderung der Metastasierung von Tumoren, wobei die Gabe der Wirk-stoffe prophylaktisch oder im Zusammenhang mit beispiels-weise einer operativen Entfernung des Primärtumors oder einer Biopsie erfolgen kann. Gegenstand ist daneben auch die Verwendung dieser Wirkstoffe zur Prophylaxe von Tumor-erkrankungen.
PCT/EP2001/012874 2000-11-07 2001-11-07 Verwendung von selektin-bindenden wirkstoffen zur behandlung von entzündlichen- und tumor-erkrankungen WO2002038168A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01989442A EP1448224A2 (de) 2000-11-07 2001-11-07 Verwendung von selektin-bindenden wirkstoffen zur behandlung von entzündlichen- und tumor-erkrankungen
CA002428141A CA2428141A1 (en) 2000-11-07 2001-11-07 Use of selectin-binding pregnancy proteins, liposomes, native mucin fragments and mimetic compounds for the treatment and prophylaxis of inflammatory diseases, for preventing metastatic spread and for the prophylaxis of tumour diseases
US10/416,061 US20040191303A1 (en) 2000-11-07 2001-11-07 Use of selectin-binding pregnancy proteins, liposomes, native mucin fragments and mimetic compounds for the treatment and prophylaxis inflammatory diseases, for preventing metastatic spread and for the prophylaxis of tumour diseases
AU2002227907A AU2002227907A1 (en) 2000-11-07 2001-11-07 Use of selectin-binding pregnancy proteins, liposomes, native mucin fragments and mimetic compounds for the treatment and prophylaxis of inflammatory diseases, for preventing metastatic spread and for the prophylaxis of tumour diseases
JP2002540750A JP2004534722A (ja) 2000-11-07 2001-11-07 炎症性疾患の治療と予防、転移の防止、および腫瘍性疾患の予防における、セレクチン結合妊娠タンパク質、リポソーム、天然ムチン断片および擬態化合物の使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10056136.5 2000-11-07
DE10056136A DE10056136A1 (de) 2000-11-07 2000-11-07 Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen

Publications (2)

Publication Number Publication Date
WO2002038168A2 WO2002038168A2 (de) 2002-05-16
WO2002038168A3 true WO2002038168A3 (de) 2004-06-10

Family

ID=7663087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/012874 WO2002038168A2 (de) 2000-11-07 2001-11-07 Verwendung von selektin-bindenden wirkstoffen zur behandlung von entzündlichen- und tumor-erkrankungen

Country Status (7)

Country Link
US (1) US20040191303A1 (de)
EP (1) EP1448224A2 (de)
JP (1) JP2004534722A (de)
AU (1) AU2002227907A1 (de)
CA (1) CA2428141A1 (de)
DE (1) DE10056136A1 (de)
WO (1) WO2002038168A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0213402A (pt) 2001-10-29 2004-10-13 Crucell Holland Bv Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero
EP1380289A1 (de) * 2002-07-10 2004-01-14 Denis Bron Verabreichungsform für pharmazeutische Agenzien
WO2006005585A2 (en) * 2004-07-12 2006-01-19 Geneprot, Inc. Secreted polypeptide species differentially expressed during pregnancy
DE102005054454A1 (de) * 2005-11-09 2007-06-28 Universität Duisburg-Essen Verwendung von Choriongonadotropin als Immunsuppressivum
GB2466428B (en) * 2008-12-16 2013-03-27 James Akira Matsumiya Viewing apparatus for a vehicle
DK2531221T3 (da) * 2010-02-03 2019-06-17 Nanopet Pharma Gmbh Polyanioniske multivalente makromolekyler til intracellulær målretning af proliferation og proteinsyntese
WO2021148983A1 (en) 2020-01-24 2021-07-29 Pfizer Inc. Anti-e-selectin antibodies, compositions and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378418A2 (de) * 1989-01-11 1990-07-18 Intermune Life Sciences, Inc. Proliferationsinhibitoren von Immunzellen
WO1993017033A1 (en) * 1992-02-19 1993-09-02 The Biomembrane Institute Inhibition of cell adhesion by chemically-defined oligosaccharides, their derivatives, mimetics, and antibodies directed thereto
WO1996029339A1 (en) * 1995-03-21 1996-09-26 Novartis Ag Fucopeptides
WO1997031625A1 (en) * 1996-03-01 1997-09-04 The Regents Of The University Of California Inhibition of selectin binding
WO1998010783A1 (en) * 1996-09-10 1998-03-19 Biomira Inc. Muc-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016290A (en) * 1973-11-12 1977-04-05 The United States Of America As Represented By The United States Energy Research And Development Administration Method of encapsulating polyaminopolycarboxylic acid chelating agents in liposomes
US4284623A (en) * 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
US4977244A (en) * 1985-06-27 1990-12-11 The United States Of America As Represented By The Department Of Health And Human Services Uromodulin and a process of purifying it
GB8821507D0 (en) * 1988-09-14 1988-10-12 Cancer Res Campaign Tech Improvements relating to peptides
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5753631A (en) * 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US5854218A (en) * 1993-05-14 1998-12-29 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
US5760000A (en) * 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
US5962424A (en) * 1995-02-21 1999-10-05 Arch Development Corporation Methods and compositions for targeting selectins
US5599915A (en) * 1995-03-21 1997-02-04 The Scripps Research Institute Sialyl Lewis X mimetics
US5643599A (en) * 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5849293A (en) * 1996-01-11 1998-12-15 Cornell Research Foundation, Inc. Use of human transferrin in controlling insulin levels
AU733692B2 (en) * 1997-02-28 2001-05-24 Regents Of The University Of California, The Inhibition of cell-cell binding by lipid assemblies
FR2789902A1 (fr) * 1999-02-24 2000-08-25 Pf Medicament PROTEINE OmpA DE KLEBSIELLA PNEUMONIAE ASSOCIEE A LA CHAINE BETA DE L'HORMONE hCG OU A UN COMPOSE IMPLIQUE DANS LA PROLIFERATION DE CELLULES TUMORALES OU DANS LA FERTILITE, UTILE DANS UNE COMPOSITION PHARMACEUTIQUE
US7994278B1 (en) * 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378418A2 (de) * 1989-01-11 1990-07-18 Intermune Life Sciences, Inc. Proliferationsinhibitoren von Immunzellen
WO1993017033A1 (en) * 1992-02-19 1993-09-02 The Biomembrane Institute Inhibition of cell adhesion by chemically-defined oligosaccharides, their derivatives, mimetics, and antibodies directed thereto
WO1996029339A1 (en) * 1995-03-21 1996-09-26 Novartis Ag Fucopeptides
WO1997031625A1 (en) * 1996-03-01 1997-09-04 The Regents Of The University Of California Inhibition of selectin binding
WO1998010783A1 (en) * 1996-09-10 1998-03-19 Biomira Inc. Muc-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. DELL ET AL.: "Structural analysis of the oligosaccharides derived from glycodelin, a human glycoprotein with potent immunosuppressive and contraceptive activities.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 41, 13 October 1995 (1995-10-13), BALTIMORE, MD, US, pages 24116 - 24126, XP002210447 *
M.N. FUKUDA ET AL.: "A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells.", CANCER RESEARCH, vol. 60, 15 January 2000 (2000-01-15), BALTIMORE, MD, US, pages 450 - 456, XP002210449 *
O. INSUG ET AL.: "Peptide mimicking sialyl-Lewis-a with anti-inflammatory activity.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 268, no. 1, 5 February 2000 (2000-02-05), ORLANDO, FL, US, pages 106 - 111, XP002210448 *

Also Published As

Publication number Publication date
DE10056136A1 (de) 2002-05-16
AU2002227907A1 (en) 2002-05-21
WO2002038168A2 (de) 2002-05-16
EP1448224A2 (de) 2004-08-25
CA2428141A1 (en) 2002-05-16
US20040191303A1 (en) 2004-09-30
JP2004534722A (ja) 2004-11-18

Similar Documents

Publication Publication Date Title
AR009958A1 (es) Composiciones adyuvantes; vacunas formuladas con dichas composiciones; el uso de dichas composiciones en la preparacion de vacunas y procedimiento parapreparar dichas vacunas.
NZ506603A (en) Adjuvant compositions comprising polyoxyethylene ether or polyoxyethylene ester
MXPA04005865A (es) Suministro de aminoglucosidos a los pulmones.
EP1025850A4 (de) Isoflavon-enthaltende zusammensetzungen
WO2002016429A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
IT8719081A0 (it) Complessi di bioflavonoidi con fosfolipidi, loro preparazione, uso e composizioni farmaceutici e cosmetiche.
HRP20040042A2 (en) Substituted oxazolidinones for combinational therapy
IL140710A0 (en) Pulmonary delivery of active agents
BR0109548A (pt) Composição de manteiga de noz com baixo teor de gordura com fibra e proteìna elevada
HUP0204349A2 (en) Novel topical oestroprogestational compositions with systemic effect
WO2007054279A3 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
WO2003000113A3 (en) Compositions and methods for the diagnosis and treatment of tumor
HK1071521A1 (en) Use of a composition comprising cis-clomiphene andtrans-clomiphene in the preparation of a medicament for increasing serum levels of testosterone
WO2003057148A3 (en) Use of biomolecular targets in the treatment and visualization of tumors
GEP20032976B (en) Artificial Peptides Having Surface Activity and Use Thereof in The Preparation of Artificial Surfactant
MY126217A (en) Composite food composition comprising a gel and process for its preparation
EP0797999A3 (de) Fettleibigkeitprotein-Formulierungen
WO2006110760A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2001078783A3 (en) Compositions comprising natural agents for treatment of cancer
WO2002038168A3 (de) Verwendung von selektin-bindenden wirkstoffen zur behandlung von entzündlichen- und tumor-erkrankungen
ES2172695T3 (es) Carboxamidas y sulfonamidas de benzofurano.
AR024564A1 (es) Composicion que comprende esfingomielinasa para el uso como una preparacion dietetica, suplemento dietario o producto farmaceutico
WO2002016602A3 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001230543A1 (en) Physiologically active compositions based upon active ingredients of basidiomycotina and araliaceae

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2428141

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002540750

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002227907

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001989442

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10416061

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001989442

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001989442

Country of ref document: EP